NorthWest Biotherapeutics Inc (NWBO)

[CogDiss 1188X]

Northwest Biotherapeutics is finally ready for prime time

It is almost two years since I attended the Miami conference. I was not prepared to recommend it to you until now. I own it; Gramercy Capital and all of our clients own it. In recent weeks, NWBO has finally completed its Phase 3 trial. The data has been locked and sent off to the statisticians for evaluation.

Knowing that a lot of people who should be dead are not just alive but thriving, the trial was allowed to run for five years after the last patient was enrolled to gather complete data. Once the statisticians have analyzed the data, the study will be unblinded to the company and in turn to us.

Then a cascade of events will ensue: 1. The company will make a presentation at the Society of NeuroOncology on Nov. 20, at a main plenary session. 2. I anticipate that likely simultaneously an article will appear in a major medical journal of the importance of Cancer, Lancet, New England Journal or JAMA. 3. This stock will be relisted on a major stock exchange, perhaps even the NYSE making it easier for institutional investors to buy the stock. 4. This drug was “fast-tracked” in the UK in 2014 and I expect that a new drug application will be filed there very shortly after the results are known. 5. Applications will also be made in Germany, USA, and Canada. 6. UK approval could come in as few as three to five months after the filing pointing to approval as a 1H 2021 event.

Right now, NWBO is valued at less than $1 billion. If the trial is successful, and we will know quickly, this undervaluation will correct rapidly. Immunomedics was recently acquired for $21 billion by Gilead with a less promising drug. 

https://www.google.com/amp/s/amp.heraldtribune.com/amp/3656047001


First article in the mainstream?

More to come...